2 Top Growth Stocks to Buy Right Now Without Any Hesitation

The article recommends Eli Lilly and Intuitive Surgical as outstanding healthcare stocks to buy. Eli Lilly is positioned as a leader in the rapidly growing weight management medicine market with approved drugs like Zepbound and Foundayo, plus promising pipeline candidates like retatrutide. Intuitive Surgical, despite recent underperformance and headwinds, is viewed as a buying opportunity due to the successful launch of its da Vinci 5 surgical system and strong long-term prospects driven by innovation and high switching costs.

07/24/2026, 12:30 AM • The Motley Fool

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering

Scribe Therapeutics, a clinical-stage biotech company focused on in vivo CRISPR technologies, priced its IPO at $15 per share, raising $128.7 million from 8.58 million shares. The company will begin trading on Nasdaq under ticker SCTX on July 24, 2026. Additionally, Sanofi agreed to purchase 500,000 shares in a concurrent private placement at the same price.

07/23/2026, 9:08 PM • GlobeNewswire

iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?

The article compares two healthcare-focused ETFs: iShares Global Healthcare ETF (IXJ) with 110 holdings offering global diversification and lower volatility, versus VanEck Biotech ETF (BBH) with 25 concentrated biotech positions delivering higher short-term returns but greater drawdown risk. IXJ is recommended for its superior long-term performance, geographic diversity, and stability despite BBH's impressive 30.8% one-year return.

07/23/2026, 3:30 PM • The Motley Fool

Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?

First Trust NYSE Arca Biotechnology Index Fund (FBT) offers concentrated exposure to 30 biotech stocks with 51.6% 1-year returns but higher volatility and a 0.55% expense ratio. Vanguard Health Care ETF (VHT) provides broader diversification across 400+ healthcare companies with lower costs (0.09% expense ratio) and dividend yield, making it better for long-term stability. FBT suits investors with high risk tolerance and biotech conviction, while VHT is recommended for those seeking healthcare as a portfolio stabilizer.

07/23/2026, 8:15 AM • The Motley Fool

Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

Cyllene Therapeutics announced the appointment of Alyssa Levin to its Board of Directors as Audit Committee Chair, along with two key executive hires: Clara Cambon-Thiebaud as VP of Regulatory Affairs and Céline Breda as VP of Chemistry, Manufacturing and Controls. These appointments strengthen the company's leadership as it advances its lead candidate EG110A toward late-stage clinical development for neurogenic bladder-related incontinence.

07/23/2026, 1:30 AM • GlobeNewswire

Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?

The article compares two healthcare-focused ETFs: Vanguard Health Care ETF (VHT) and iShares U.S. Pharmaceuticals ETF (IHE). VHT offers broader diversification with 411 holdings and a lower 0.09% expense ratio, while IHE provides concentrated pharmaceutical exposure with 56 holdings and has delivered superior 5-year returns (11.8% vs 5.4%). The author recommends IHE as the better buy for 2026 due to stronger recent performance and lower maximum drawdown, despite VHT's cost advantages.

07/22/2026, 4:33 PM • The Motley Fool

As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026?

The article compares two healthcare-focused ETFs: Vanguard Health Care ETF (VHT) and Invesco Pharmaceuticals ETF (PJP). VHT offers broader sector exposure with 411 holdings, a lower expense ratio of 0.09%, and higher dividend yield of 1.60%. PJP focuses narrowly on 29 pharmaceutical stocks with a 0.57% expense ratio and 0.90% yield. Despite VHT's cost advantages, PJP has significantly outperformed over 3 and 5-year periods (17.3% and 9.1% returns respectively), leading the author to recommend PJP as the better buy for 2026.

07/22/2026, 3:13 PM • The Motley Fool

Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell.

The article recommends three dividend stocks suitable for long-term buy-and-hold investors: Pfizer, which is developing new blockbuster drugs and entering the obesity drug market; Coca-Cola, with 64 years of consecutive dividend increases and a resilient business model; and Brookfield Renewable, which offers recurring income from renewable energy assets with 5-9% annual dividend growth targets.

07/22/2026, 11:23 AM • The Motley Fool

New study finds GLP-1 receptor agonists associated with lower risk of alcohol-related hospitalization among adults with alcohol use disorder

A multi-system study analyzing electronic health records from over 40,000 adults with alcohol use disorder found that GLP-1 receptor agonists (semaglutide and tirzepatide) were associated with 22-26% lower risk of alcohol-related hospitalization in patients with type 2 diabetes, and 32% lower risk in patients with obesity, compared to alternative treatments. Researchers emphasize the need for randomized clinical trials to establish causation.

07/21/2026, 6:45 PM • GlobeNewswire

"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks.

Novo Nordisk has filed a federal lawsuit against Eli Lilly, alleging deceptive advertising in GLP-1 weight-loss drug marketing. Novo claims Lilly's ads unfairly compare outdated lower doses of Wegovy to higher doses of Zepbound, ignoring the FDA-approved 7.2 mg Wegovy dose (approved March 2025) which shows comparable weight loss results. Lilly maintains its ads are accurate based on the 2024 SURMOUNT-5 head-to-head trial. The lawsuit seeks an injunction, corrective advertising, and damages, though analysts believe the impact on both stocks is likely minimal.

07/21/2026, 5:34 PM • The Motley Fool

Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?

iShares Global Healthcare ETF (IXJ) offers broad diversification across 110 global healthcare companies with a lower 0.40% expense ratio, while First Trust NYSE Arca Biotechnology Index Fund (FBT) concentrates on 30 biotech companies with higher growth potential but greater volatility. IXJ suits defensive investors seeking stable exposure to established pharma giants, while FBT appeals to those betting on biotech breakthroughs despite higher risk.

07/21/2026, 2:12 PM • The Motley Fool

IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?

IXJ and RSPH are two healthcare ETFs with different strategies: IXJ uses cap-weighted global exposure with larger pharmaceutical companies, offering higher dividends (1.47%) and lower volatility (beta 0.52), while RSPH employs equal-weighting of S&P 500 healthcare stocks, providing stronger 1-year returns (21.01% vs 18.29%) but higher risk (beta 0.81). The choice depends on investor goals—IXJ suits conservative/income-focused investors, while RSPH appeals to growth-oriented investors willing to accept volatility.

07/21/2026, 1:32 PM • The Motley Fool

PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight

A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-L1 inhibitor drugs across various clinical stages. The report highlights major pharmaceutical players advancing pipeline therapies for multiple cancer indications, with approximately 15+ drugs in late-stage development and 30+ in mid and early stages. Recent developments include FDA breakthrough designations and positive clinical trial results for combination therapies.

07/21/2026, 1:00 PM • GlobeNewswire

Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing

Novo Nordisk offers an attractive 3.5% dividend yield backed by a shifting business model focused on volume-driven growth in GLP-1 weight-loss drugs. Despite 2026 being a transition year with pricing pressures and generic competition, the company's strong pill formulation demand and solved supply issues position it well. The stock trades below five-year valuation averages, making it appealing for dividend investors seeking recurring income similar to its insulin business.

07/21/2026, 9:15 AM • The Motley Fool

Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?

Eli Lilly's stock has surged above $1,000, driven primarily by its dominant position in the weight loss drug market. With the stock trading at these elevated levels, analysts speculate whether the company might announce a stock split to make shares more accessible to investors. While Lilly hasn't executed a stock split since 1997, a move could broaden its investor base and signal management confidence in future growth, particularly given recent launches like Foundayo and strong trial results for retatrutide.

07/20/2026, 2:10 PM • The Motley Fool